New York University

Richard Bonneau

Paramjit S Arora

Brooke Bullock Lao

Kevin Drew

Kent Kirshenbaum

Timothy W Craven

Jin Kim Montclare

Danielle Guarracino

Carlo Yuvienco

Kyunghyun Cho

P Douglas Renfrew

Ching-Yao Yang

Susan Logan

Amanda Kasper

Vladimir Gligorijevic

Jeffrey A Schneider

Provided are peptoid-peptide macrocycles. The peptoid-peptide macrocycles may have inhibitory activity towards the Wnt signaling pathway. The Wnt signaling pathway is associated with cancer and other diseases and conditions. Such diseases include, for example, pulmonary fibrosis. Also described are methods of making the peptoid-peptide macrocycles, compositions containing the peptoid-peptide macrocycles, and methods of using the peptoid-peptide macrocycles.

Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same

A protein design system includes one or more processors configured to modify, by a modifier, an input sequence corresponding to a protein, the input sequence comprising a data structure indicating a plurality of amino acid residues of the protein; map, by an encoder, the modified sequence to a latent space; predict, by a length predictor, a length difference between the mapped sequence and a target sequence based on at least one target function of the target sequence; identify, by a function classifier, at least one sequence function of the modified sequence; transform, by a length transformer, the modified sequence based on the length difference and the at least one sequence function; and generate, by a decoder, a candidate for the target sequence based on the transformed sequence.

Function guided in silico protein design

The present invention relates to oxopiperazines that mimic helix &#x3b1;B of the C-terminal transactivation domain of HIF1&#x3b1;. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1&#x3b1; with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression

The present invention relates to oligooxopiperazines for modulating the p53-Mdm2 interaction. Exemplary oligooxopiperazines include those of Formula IA, Formula IB, and Formula IC below (wherein the various substituents are as defined herein). Methods of using the oligooxopiperazines are also disclosed. 

Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction

The present invention relates to oxopiperazines that mimic helix &#x3b1;B of the C-terminal transactivation domain of HIF1&#x3b1;. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1a with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Oxopiperazine helix mimetics for control of Hypoxia-Inducible gene expression

Miniature protein scaffolds and compositions thereof (e.g., vaccine formulations) and methods of using same are described herein. In a particular embodiment, the miniature protein scaffold comprises an isolated &#x3b2;-strand connected via a loop to a left-handed poly proline type-II (PPII) helix formed in the absence of proline residues.

Miniature protein scaffolds and methods for use thereof

The instant invention provides methods and related compositions for identifying polypeptides with improved stability and/or enzymatic activity in comparison to native forms, wherein the identified polypeptides comprise one or more non-natural amino acids. In certain embodiments, the present invention relates to novel phosphotriesterase enzymes comprising one or more non-natural amino acids. In a particular embodiment, the instant invention provides novel phosphotriesterase enzymes with greater stability and/or enhanced activity in comparison to native forms of the enzyme. The present invention also relates to compositions comprising novel phophotriesterase enzymes, such as prophylactics, decontaminants, animal feedstocks, and assay kits.

Growing community of inventors

New York, NY, United States of America

Richard Bonneau